IL273698B2 - Methods for selectively expanding cells expressing a tcr with a murine constant region - Google Patents

Methods for selectively expanding cells expressing a tcr with a murine constant region

Info

Publication number
IL273698B2
IL273698B2 IL273698A IL27369820A IL273698B2 IL 273698 B2 IL273698 B2 IL 273698B2 IL 273698 A IL273698 A IL 273698A IL 27369820 A IL27369820 A IL 27369820A IL 273698 B2 IL273698 B2 IL 273698B2
Authority
IL
Israel
Prior art keywords
cells
tcr
constant region
human
express
Prior art date
Application number
IL273698A
Other languages
English (en)
Hebrew (he)
Other versions
IL273698A (en
IL273698B1 (en
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IL273698A publication Critical patent/IL273698A/en
Publication of IL273698B1 publication Critical patent/IL273698B1/en
Publication of IL273698B2 publication Critical patent/IL273698B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL273698A 2017-10-05 2018-09-24 Methods for selectively expanding cells expressing a tcr with a murine constant region IL273698B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762568339P 2017-10-05 2017-10-05
PCT/US2018/052432 WO2019070435A1 (en) 2017-10-05 2018-09-24 METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION

Publications (3)

Publication Number Publication Date
IL273698A IL273698A (en) 2020-05-31
IL273698B1 IL273698B1 (en) 2025-03-01
IL273698B2 true IL273698B2 (en) 2025-07-01

Family

ID=63841049

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273698A IL273698B2 (en) 2017-10-05 2018-09-24 Methods for selectively expanding cells expressing a tcr with a murine constant region

Country Status (13)

Country Link
US (1) US12227554B2 (cg-RX-API-DMAC7.html)
EP (2) EP3692140B1 (cg-RX-API-DMAC7.html)
JP (2) JP2020535832A (cg-RX-API-DMAC7.html)
KR (1) KR102757789B1 (cg-RX-API-DMAC7.html)
CN (1) CN111417720B (cg-RX-API-DMAC7.html)
AU (1) AU2018345400B2 (cg-RX-API-DMAC7.html)
CA (1) CA3077595A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960313T3 (cg-RX-API-DMAC7.html)
FI (1) FI3692140T3 (cg-RX-API-DMAC7.html)
IL (1) IL273698B2 (cg-RX-API-DMAC7.html)
MA (1) MA50748A (cg-RX-API-DMAC7.html)
SG (1) SG11202003112QA (cg-RX-API-DMAC7.html)
WO (1) WO2019070435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230124983A (ko) * 2020-12-22 2023-08-28 네오진 테라퓨틱스 비.브이. 유전적으로 조작된 세포를 추적하기 위한 펩타이드마커
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
US20250145950A1 (en) * 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU6969096A (en) * 1995-09-05 1997-03-27 General Hospital Corporation, The Monoclonal lymphocytes and methods of use
DE19905048A1 (de) 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie
JP2003274960A (ja) * 2000-02-03 2003-09-30 Japan Science & Technology Corp 可溶性ｔ細胞受容体タンパク質およびその作成方法
JP2003276960A (ja) * 2002-03-26 2003-10-02 Mitsubishi Electric Corp エレベーター制御システム
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
AU2004289316B2 (en) * 2003-11-10 2011-03-31 Altor Bioscience Corporation Soluble TCR molecules and methods of use
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
US8216565B2 (en) 2007-01-12 2012-07-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services GP100-specific T cell receptors and related materials and methods of use
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
ES2876176T3 (es) 2010-09-21 2021-11-12 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP3828197B1 (en) 2012-05-22 2024-10-02 The United States of America, as represented by the Secretary, Department of Health and Human Services Pharmaceutical composition comprising host cells encoding anti-ny-eso-1 t cell receptors
PT2895509T (pt) * 2012-09-14 2020-03-13 Us Health Recetores de células t que reconhecem mage-3 restrito a mhc de classe ii
ES2745472T3 (es) * 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
US10174098B2 (en) * 2014-05-29 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E7 T cell receptors
EP3848456A1 (en) * 2014-10-02 2021-07-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
KR20170100517A (ko) * 2014-11-20 2017-09-04 유엠씨 우트레크트 홀딩 비.브이. 외래 면역 수용체를 갖는 조작된 T 세포의 농축(enriched)을 위한 항체 및 조작된 T 세포의 디플리션에 사용하기 위한 항체의 용도
US11207394B2 (en) 2014-11-26 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
EP3350213B1 (en) 2015-09-15 2021-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
ES2906795T3 (es) 2016-04-26 2022-04-20 Us Health Receptores de células T anti-KK-LC-1
HUE060121T2 (hu) 2016-08-02 2023-01-28 The U S A As Represented By The Secretary Anti-KRAS-G12D T-sejt receptorok

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENIGER, DREW C., ET AL., STABLE, NONVIRAL EXPRESSION OF MUTATED TUMOR NEOANTIGEN-SPECIFIC T-CELL RECEPTORS USING THE SLEEPING BEAUTY TRANSPOSON/TRANSPOSASE SYSTEM, 5 March 2016 (2016-03-05) *

Also Published As

Publication number Publication date
JP2024050551A (ja) 2024-04-10
EP4269595A3 (en) 2023-12-06
WO2019070435A8 (en) 2020-01-30
CN111417720A (zh) 2020-07-14
EP3692140A1 (en) 2020-08-12
EP4269595A2 (en) 2023-11-01
AU2018345400A1 (en) 2020-05-07
WO2019070435A1 (en) 2019-04-11
KR102757789B1 (ko) 2025-01-20
ES2960313T3 (es) 2024-03-04
JP2020535832A (ja) 2020-12-10
US20200254018A1 (en) 2020-08-13
US12227554B2 (en) 2025-02-18
EP3692140B1 (en) 2023-07-19
CN111417720B (zh) 2025-02-07
JP7747724B2 (ja) 2025-10-01
IL273698A (en) 2020-05-31
KR20200064107A (ko) 2020-06-05
AU2018345400B2 (en) 2024-06-20
MA50748A (fr) 2020-08-12
CA3077595A1 (en) 2019-04-11
IL273698B1 (en) 2025-03-01
SG11202003112QA (en) 2020-05-28
FI3692140T3 (fi) 2023-10-11

Similar Documents

Publication Publication Date Title
Bergqvist et al. Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses
IL273698B1 (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
EP4495133A3 (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
JP2019536461A5 (cg-RX-API-DMAC7.html)
EP4309739A3 (en) Core/shell structure platform for immunotherapy
WO2018204493A1 (en) Compositions and methods for gene editing in t cells using crispr/cpf1
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
JP2004526459A5 (cg-RX-API-DMAC7.html)
RU2015138483A (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
WO2007016130A3 (en) A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
NZ611600A (en) Means and methods for producing high affinity antibodies
MY200528A (en) Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
MX2021005481A (es) Metodos para aislar y expandir celulas.
Sabatino et al. Production of anti-CD19 CAR T cells for ZUMA-3 and-4: phase 1/2 multicenter studies evaluating KTE-C19 in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL)
Faliti et al. Interleukin-2-secreting T helper cells promote extra-follicular B cell maturation via intrinsic regulation of a B cell mTOR-AKT-Blimp-1 axis
JP2013505296A5 (cg-RX-API-DMAC7.html)
MY202687A (en) Pharmaceutical chimeric receptor composition and method thereof
Chen Efficient gene editing in primary human T cells
JP2020535832A5 (cg-RX-API-DMAC7.html)
TW200611706A (en) Cytotoxic t lymphocyte
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
MX2025003245A (es) Metodos para tratar esclerosis multiple usando celulas t autologas
WO2022040631A1 (en) Methods for isolating cd8+ selected t cells